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Abstract 
P2Y receptors are expressed in virtually all cells and tissue types and mediate an 
astonishing array of biological functions including platelet aggregation, smooth muscle cell 
proliferation and immune regulation. The P2Y receptors belong to the GPCR superfamily 
and are composed of eight members encoded by distinct genes that can be subdivided into 
two groups based on their coupling to specific G-proteins. Extensive research has been 
undertaken to find modulators of P2Y receptors, although to date there have only been a 
limited number of small molecule P2Y receptor antagonists that have been approved by 
drug/medicines agencies. This Perspective reviews the known P2Y receptor antagonists, 
highlighting oral drug-like receptor antagonists, and considers future opportunities for the 
development of small molecules for clinical evaluation. 
Introduction 
Although nucleotides, such as adenosine-5’-triphosphate (ATP) and uridine triphosphate 
(UTP) are important intracellular molecules, they are also released into extracellular fluids by 
various mechanisms. The receptors for these extracellular nucleotides have been 
progressively characterized and classified as purinergic receptors.1 The subdivision of these 
purinergic receptors into P1 (adenosine) and P2 (ATP, ADP) was originally proposed by 
Burnstock in 19782 and further subdivision of the P2 receptors between P2X and P2Y was 
made in 1985.3 It is now well established that signalling by extracellular nucleotides is 
mediated by two families of receptors, where P2Y receptors are metabotropic G protein-
 coupled receptors (GPCRs) and P2X receptors are trimeric ion channels.4 The P2Y 
receptors belong to the GPCR superfamily and possess the characteristic molecular 
topology of an extracellular N-terminus, an intracellular C-terminus and seven 
transmembrane spanning loops.5 However, in comparison to other GPCR families, P2Y 
receptors show limited sequence homology; possibly explaining the differences in ligand 
selectivity and specificity for the relevant G-protein they signal through. In addition, P2Y 
receptors are found to be expressed in virtually all cells, in all tissue types and mediate an 
astounding array of biological functions including platelet aggregation, smooth muscle cell 
proliferation and immune regulation. The discovery of oral, drug-like6-7 compounds with 
favourable ADME (absorption, distribution, metabolism, and excretion) properties8 for these 
receptors, specifically antagonists of the P2Y12 receptor that have proven therapeutic benefit 
in various disease states, could address many unmet areas of clinical need.9 
The P2Y family is composed of eight members encoded by distinct genes that can be 
subdivided into two groups based on their primary signalling through specific coupled G-
proteins. From a phylogenetic and structural (i.e. protein sequence) perspective, two distinct 
P2Y receptor sub-groups have been characterized by the relatively high level of sequence 
divergence. The first sub-group includes the P2Y1,2,4,6,11 receptors and the second sub-group 
encompasses the P2Y12,13,14 receptor subtypes. In addition, the various P2Y receptors differ 
by their selectivity for distinct nucleotides (Table 1). P2Y11 is an ATP receptor, whereas 
P2Y1, P2Y12, and P2Y13 are ADP receptors. P2Y4 and P2Y6 are pyrimidine nucleotide 
receptors activated by UTP and UDP respectively. P2Y2 is a dual ATP and UTP receptor. 
P2Y14 is a receptor for UDP-glucose and other nucleotide sugars as well as for UDP itself.  
Table 1: Properties of human P2Y receptors. 
Receptor Tissue distribution Agonist G 
Protein 
P2Y1 wide, including platelets, CNS, heart, skeletal ADP Gq 
 muscle, GI tract 
P2Y2 wide, including lung, heart, skeletal muscle, 
kidney, brain 
ATP=UTP Gq 
P2Y4 placenta, lung, vascular smooth muscle UTP Gq 
P2Y6 wide, including brain, lung, heart, placenta, spleen, 
intestine 
UDP Gq 
P2Y11 spleen, intestine, dendritic cells ATP Gq + Gs 
P2Y12 platelets, brain ADP Gi 
P2Y13 brain, spleen ADP Gi 
P2Y14 wide including brain, heart, adipose tissue, 




For further information relating to the specificity of P2YRs see Alexander et al10 
This perspective aims to examine the various approaches used to discover drug-like 
antagonists of P2Y receptors and builds on recent reviews in the area concentrating on P2Y 
receptor agonists and the early nucleotide containing modulators.11 Recently, X-ray crystal 
structures of ligand-bound P2Y112 and P2Y1213-14 receptors have been published. It is hoped 
that structural information resulting from these disclosures can assist in the design of new 
modulators for P2Y receptor subtypes, as many of the reported modulators still lack the 
potency and selectivity for viable chemical drug-like leads. Oral drug design has been 
hampered by the importance of retaining the negatively charged phosphates of nucleotides 
for their interaction with the P2Y receptors. This presents huge issues for drug development 
because of their metabolic instability, low bioavailability, nonspecific binding to biological 
membranes, and chemically due to their demanding purification.  To date, the only clinically 
proven role for P2Y receptor antagonists lays in the antithrombotic area, where extracellular 
nucleotide signalling has been shown to be involved in platelet aggregation. Extracellular 
ADP has a crucial role in platelet activation through activation of cell surface P2Y1 and P2Y12 
receptors, resulting in adherence to sites of damage when blood vessel injury occurs. In so 
 doing, platelets secrete several factors that initiate clot formation and recruit other platelets 
to the point of injury. Based on this, several antagonists for each of these receptors show 
anti-thrombotic activities. However, to date only P2Y12 receptor antagonists have been 
successfully developed for clinical use.  
The development of clinically relevant P2Y12 receptor antagonists and further case histories 
for the discovery of other P2Y receptor subtype antagonists will be presented in this 
perspective. Each sub-section, containing a brief introduction to the underlying 
pharmacology and potential clinical benefit for the P2Y receptor antagonist, is followed by a 
detailed study of the search for effective orally bioavailable, drug-like molecules.  
Drug-like antagonists of the P2Y1 receptor (P2Y1R) 
Advances in platelet biology15 revealed that ADP played a crucial role in platelet function. 
Therefore, receptor antagonists of the two ADP receptors, P2Y1 and P2Y12, may provide 
antithrombotic efficacy16 with reduced bleeding liabilities. Through a Gi-dependent pathway, 
P2Y12R activation is responsible for mediating the inhibition of adenylyl cyclase, which 
sustains platelet aggregation. Through a Gq-dependent pathway, P2Y1R activation is 
responsible for calcium mobilisation, which causes platelet shape change and initiates 
reversible aggregation.17 It has been demonstrated in pre-clinical studies using P2Y1-
deficient (P2Y1 -/-) mice, and by using selective nucleotide-derived P2Y1R antagonists such 
as 1 (MRS2179)18 (Figure 1), that a complete blockade of ADP-induced platelet aggregation 
occurs leading to an effective reduction of arterial thrombosis with a moderate prolongation 
of the bleeding time.19-20,21,22  Inhibition of the P2Y1R is therefore a promising approach for 
the discovery of new antithrombotic drugs.23-24  
In the search for selective antagonists of the P2Y1R, structural modifications were made on 
the natural agonist 2 (adenosine diphosphate, ADP). In the first reported work in this field, 
building on the observation that 3 was a weak partial agonist,25 4 was shown to be an 
antagonist of the P2Y1R.25 Substitution of the ribose with an acyclic group afforded 5, a 
 potent bisphosphate antagonist (Figure 1).26 These compounds proved useful tools for 
interrogating the scope of modulating the P2Y1R. However, their pharmacokinetic properties 
may not make them ideal oral, drug-like candidates.  A series of adenosine derivatives 5a-b 
were shown to have weak antagonist activity when linked to aspartic acid through a 
carbamate.27 Further studies in these areas delivered 6 (MRS2279) and 7 (MRS2500)28 as 
useful tool compounds to probe the mechanism and highlight the potential clinical 
significance of P2Y1R antagonism.29 
 
Figure 1: The natural agonist 2 (ADP) and a selection of nucleoside-based P2Y1R 
antagonists. 
The following section focuses on the study of P2Y1R antagonists specifically aimed at the 
identification and development of oral drugs.  
 Scientists at Bristol-Myers Squibb (BMS) have reported the discovery and development of a 
series of potent, selective and bioavailable diarylurea P2Y1R antagonists. In their discovery 
program a high throughput screening (HTS) effort, using >1 million compounds against the 
human P2Y1R, revealed that diarylurea 830 had good affinity and binding selectivity toward 
the P2Y1R versus P2Y12R (P2Y1 Ki = 75 nM, P2Y12 Ki > 70 μM). 
 
In light of its profile, compound 8 was chosen as the starting point for further modification. 
The hit series was amenable to rapid exploration by parallel synthesis, initially through 
substitution of the phenyl ring attached to the urea group. In this synthetic strategy, 
isocyanate 9 was reacted with a diverse array of 96 amines to afford a series of urea 
derivatives (such as 10a-i) that rapidly generated a structure-activity relationship (SAR). To 
explore substitution of the phenyl ether group, the 2,4-difluorophenyl urea was kept constant 
and a range of substituted 3-aminopyridines 11a-i were condensed with 2,4-difluorophenyl 
isocyanate, key results from these arrays are summarized in Table 2. 
Table 2: Parallel synthesis and exploration of initial hit 8. 
 
Compound R1 hP2Y1 Ki Compound R2 hP2Y1 Ki 
 (nM)a (nM)a 
10a Ph 171 12a 3-CF3 75 
10b 2-F-Ph 47 12b H 2000 
10c 2-Cl-Ph >5000 12c 2-t-Bu 18 
10d 3-F-Ph 607 12d 3-t-Bu 33 
10e 4-Cl-Ph 69 12e 2-i-Pr 28 
10f 4-MePh 48 12f 2-Et 77 
10g 4-OCF3-Ph 313 12g 2-CF3 172 
10h CH2Ph >5000 12h 4-CF3 >5000 
10i CH2CH2Ph >5000 12i 4-Me >5000 
aMeasured by displacement of [-33P]-2-MeS-ADP binding to cloned hP2Y1 receptors 
From this work, it was demonstrated that mono-substitution was preferred for activity at the 
distal aromatic group (R1) and that aliphatic substituents were not tolerated in this position. 
Data also supported the concept that lipophilicity at the ortho-position of the phenyl ether 
(R2) was required for affinity. The importance of the ether link between the phenyl and 
pyridyl rings was also explored by replacing it with either a thio-ether or amino variants. 
Whilst substitution with sulphur afforded a 3-fold drop in affinity, replacement with nitrogen 
resulted in a 20-fold loss, and N-methylation resulted in a more significant loss (Figure 2). 
 
Figure 2: Structure activity relationship for the replacement of the oxygen atom with sulfur or 
nitrogen. 
A follow-on array was then synthesized using a combination of eight preferred substituents 
from the phenyl ether group and the aromatic ring attached to the urea group. Using a 
 human platelet rich plasma assay (hPRP), these compounds demonstrated a clear trend that 
combination of a lipophile at the ortho-position alongside substitution of the phenyl urea at 
the para-position gave receptor antagonists, with several compounds displaying micro-molar 
activity. In order to ensure that the anti-platelet activity was due exclusively to P2Y1R 
antagonism, all compounds were tested for antagonism at other P2Y receptors such as 
P2Y2, P2Y6, P2Y11, P2Y12 and P2Y14. Compounds with good in vitro P2Y1R binding affinity 
and functional activity were evaluated to determine their metabolic stability. From these 
studies, compound 13 (BPTU) showed reasonable metabolic stability in rats and was 
progressed to an in vivo rat pharmacokinetic (PK) study.  This compound showed modest 
bioavailability (F = 18%) when dosed at 30 mg/kg and the compound was subsequently 
progressed to a rat antithrombotic assay (Figure 3).  
 
Figure 3: Rat in vivo PK study on compound 13. Vss is the volume of distribution at steady-
state. 
Compound 13 clearly improved blood flow and reduced thrombus weight in a dose 
dependent manner showing a maximum of 68 ± 7% thrombus weight reduction compared to 
vehicle using a 10 mg/kg bolus followed by 10 mg/kg/h infusion. Ex vivo platelet aggregation 
responses to ADP were also significantly inhibited at all antithrombotic doses.  
Diarylurea-containing compounds of the type shown (Figures 2-3) are generally associated 
with poor solubility at physiological pH. BMS scientists addressed this issue by addition of 
amine-containing, water-solubilizing groups (R3) onto the distal phenyl ring (Figure 4).31 
  
 
Figure 4: Incorporation of an amine as a water-solubilizing group to improve physico-
chemical properties of the urea derivatives. 
This afforded a series of compounds, as illustrated by 14 and 15, with comparable binding 
affinities when compared to the parent 13. Compound 14 was chosen as the new lead 
compound as it possessed similar levels of activity in the platelet aggregation assay (IC50 2.9 
M at 25 M ADP) but had significantly higher solubility. However, further profiling of 14 
showed it was metabolically unstable in rat and human liver microsomes and displayed high 
inhibition against several GPCR targets [ca. 90% inhibition (at 10 M) 5-HT2A, 5-HTT, -2A 
adrenoreceptor and -1D adrenoreceptor]. Further investigation revealed 15 as a more 
metabolically-stable compound with enhanced rat bioavailability (F = 40%), due in part to the 
increase in aqueous solubility. Unfortunately, 15 also had similar off-target activity, as well as 
showing activity against the hERG potassium ion channel.  
In order to address the poor physico-chemical properties of their lead compounds, scientists 
at BMS looked into bioisostere replacements of the core urea moiety. In a series of papers 
they explored replacement of the urea with amino thiadiazole32 16 and 2-aminothiazole33 17 
mimetics (Figure 5). 
  
Figure 5: Bioisosteric replacement of the urea group: a) 2-amino-3,4-thiadiazole 
replacement and b) 2-aminothiazole replacement 
High P2Y1R antagonism was demonstrated for a range of azole bioisosteric replacements 
(e.g. 16). Several five-membered heterocycles were used as replacement for the urea 
moiety, with comparable levels of P2Y1R antagonism and ADP-induced aggregation activity. 
These receptor antagonists suffered from the same poor physico-chemical properties as the 
previous lead series (high lipophilicity including poor aqueous solubility <1 g/mL at pH 6.5) 
and were not pursued further. In the case of the 2-aminothiazole bioisosteric replacements, 
a series of new analogues were discovered with excellent P2Y1R binding affinity. Several of 
the analogues demonstrated moderate inhibition of platelet aggregation, with compound 17 
showing a reasonable rat PK profile (CL 6.7 mL/min/kg; T1/2 2.1 h, F 27%). However, poor 
solubility and high plasma protein binding (99.9% bound) may have contributed to the 
modest activity seen in the human serum platelet aggregation assay (IC50 17 M) and this 
series was not pursued.  
In another approach to address the poor physico-chemical properties inherent in the biaryl 
urea lead compounds, incorporation of an amine containing, water-solubilizing group into the 
phenyl ether portion of the core structure was explored (Figure 6).  
  
Figure 6: Changes to the phenyl ether portion of 13 to increase water solubility 
Compounds (18-20) displayed similar hP2Y1R antagonism to that of 13, however improved 
physico-chemical properties resulted in good functional activities as well as improved 
aqueous solubility. From this set of compounds, piperidine 20 showed the best overall profile 
and favourable PK parameters (Table 3).34 
Table 3: In vitro data and rat PK profile for the diarylureas 18-20.  
















18c 11 2.5 3 48 22 14 16 100 
19c 57 1.2 270 84 10 1.7 13 99.7 
20d 16 2.4 105 18 14 11 89 99.9 
aPlatelet aggregation (PA) was tested with 2.5 μM of ADP. bPlasma protein binding (PPB). C 
Cassette dosed 0.5 mg/kg (i.v./p.o.) d2 mg/kg (i.v.), 5 mg/kg (p.o.) 
In a continuing theme, a range of conformationally-constrained, anilino-substituted 
diarylureas were synthesized to generate a new series of potent and selective P2Y1R 
antagonists. These compounds possessed an oral antithrombotic effect with mild bleeding 
liability in rat thrombosis and homeostasis models (Figure 7).35  
  
Figure 7: Evolution of new conformational constrained, ortho-anilino diarylurea 23. 
In the evolution of compound 23, compounds 21-22 demonstrated good P2Y1R antagonism 
(21 hP2Y1 Ki = 8.7 nM, 22 hP2Y1 Ki = 20.3 nM). It is interesting to note that among these 
ring-constrained analogues, the aryl compound 21 had slightly enhanced activity at the 
P2Y1R and this seemed to be a general trend observed within this series of compounds. 
After further optimization, 23 was identified, with an excellent overall profile (23, hP2Y1 Ki = 
4.3 nM, hP2Y1; PA = 4.9 M (at 10M ADP); solubility 4 g/mL; rat PK: CL 9.1 mL/min/kg; 
T1/2 7.5 h; F 32%). Compound 23 inhibited arterial thrombus formations and improved blood 
flow in a dose-dependent manner when administered by either IV or PO routes. Maximum 
thrombus weight reductions of 66% and 64% were observed in comparison to vehicle at 
doses of 0.6 mg/kg + 2.25 mg/kg/h (IV) and 10 mg/kg (PO), respectively. In these same rat 
models, a 20 mg/kg oral dose of clopidogrel reduced carotid artery thrombus weight by 67% 
and prolonged mesenteric bleeding time by 8.2-fold. These results suggested that inhibition 
of P2Y1 by 23 compared favourably to the antithrombotic and haemostatic effects of 
clopidogrel - a clinically established P2Y12R antagonist. 
In a further disclosure, potency in the spiropiperidine indoline-substituted diarylureas was 
enhanced through the introduction of a 7-hydroxyl substitution on the spiropiperidinyl 
indoline chemotype. Further SAR studies were conducted to improve pharmacokinetics and 
potency, resulting in the identification of 24 (P2Y1 calcium mobilization assay = 0.12 nM; PA 
= 0.13 M (at 10M ADP); solubility 680 g/mL; CL 7.3 mL/min/kg; T1/2 8.4 h; F 23%), a 
compound that demonstrated a robust antithrombotic effect in vivo and improved bleeding 
 risk profile compared to the P2Y12R antagonist clopidogrel in a rat bleeding model.36 This 
exciting improvement in activity led to investigation of a series of urea bioisosteres of the 
diarylurea lead 24, culminating in the discovery of a series of 2-amino-1,3,4-thiadiazoles, 
such as compound 25 (P2Y1 Ki 16 nM; PA 0.45 M (at 10 M ADP); rat PK: CL 4.0 
mL/min/kg; T1/2 24 h; F 22% (cassette dosed 0.5 mg/kg (p.o.)), as potent P2Y1R antagonists; 
the first series of non-urea containing P2Y1R antagonists.37  
 
Several analogs of 25 were shown to have more favourable PK profiles, such as higher 
maximal trough concentration (Ctrough), lower CL, smaller Vss, and similar bioavailability 
compared with 25.  
Further optimization of 25, by introducing 4-aryl groups at the hydroxylindoline in two neutral 
and basic sub-series, have been described.38-39 In the neutral series, 26 had excellent 
potency and a highly desirable PK profile. Meanwhile, in the basic series, 27 (BMS-884775) 
had an improved PK profile (Figure 8).  
  
Figure 8: Discovery of 27 – a potent and orally bioavailable P2Y1R antagonist (n.b. no dose 
given for the PK studies). 
Scientists at Pfizer have reported a series of potent and orally bioavailable diarylurea P2Y1R 
antagonists40 resulting from an HTS campaign. The HTS hits (28 and 29) were further 
explored to deliver aryloxypyrazole 30 as a suitable template for further elaboration (Figure 
9). 
Figure 9: Discovery of the aryloxypyrazole template (such as 30) for further elaboration 
During their optimization project, attention was paid to the A- and B-rings of the template. 
Interestingly, substitution in the ortho-position of the A-ring increased binding affinity and 
was preferred over meta- and para-substitution, with either small lipophilic or halogen 
substituents being optimal. Limited examination of the B-ring was undertaken at this time. 
However, it was noted that larger lipophilic substituents in the pyrazole 3-position led to 
 inactivity, thus the 3-methyl substitution was preferred. Subsequent optimization then 
focussed on the D-ring while maintaining the optimal substitution on the A- and B-rings 
(Figure 10). 
 
Figure 10: Lead optimization of the aryloxypyrazole template 
Compound 31 had good in vitro metabolic stability and was further evaluated for its rat PK 
where it demonstrated a very favourable profile (CL 81 mL/min/kg; Vds 15.7 (L/kg); T1/2 2.8 h; 
F 59%). This compound was progressed to a rat arterial injury model where it resulted in a 
dose-dependent decrease in both the incidence of occlusive thrombus formation and the 
average time to occlusion. It is interesting to note that high affinity was achieved when 
lipophilic groups were incorporated at the para-position of the D-ring (32, hP2Y1 Ki = 0.03 
M), whereas a more polar substituent (33, hP2Y1 Ki > 10 M) led to a substantial loss in 
activity. When heterocyclic replacements were made in the C-ring, it was discovered that 
substitution with a pyridyl group afforded compounds (e.g. 34) with reasonable activity.  
A series of HTS-derived diarylurea P2Y1R antagonists were reported by scientists at 
GlaxoSmithKline (GSK).40 In their work, they described the discovery of a hit (35) which was 
optimized to give a series of benzofuran-substituted urea derivatives e.g. 36 (Figure 11). 
  
Figure 11: A series of HTS-derived diarylurea P2Y1R antagonists 
Scientists at GSK also reported on a non-urea containing series of receptor antagonists, 
once more obtained as a result of HTS.41 A high throughput calcium mobilization assay 
employing a fluorescent imaging plate reader (FLIPR) identified tetrahydro-4-quinolinamine 
37 as an antagonist of hP2Y1R. Exploration of this screening hit led to the identification of 
urea 38 where the importance of the absolute stereochemistry was highlighted through the 
separation of the enantiomers through chiral HPLC and it was discovered that all P2Y1R 
antagonism was derived from a single enantiomer (Figure 12). 
  
Figure 12: Evolution of the HTS-derived lead to the active single enantiomer 38 
Compound 38 was progressed to a platelet aggregation assay and was shown to inhibit 
ADP-induced aggregation with an IC50 = 504 nM. 
 In a seminal paper, researchers have established the X-ray co-crystallised structure of 
inhibitors bound into the hP2Y1R.12 Structures of the hP2Y1R in complex with either a 
nucleotide antagonist 1 (2.7Å resolution) or a non-nucleotide antagonist 13 (2.2Å resolution) 
reveals two distinct ligand-binding sites. Interestingly 13 was originally identified by a radio-
ligand binding assay and described as a competitive antagonist.  Antagonist 1 occupies a 
binding site within the seven transmembrane bundles of the P2Y1R, and 13 binds to an 
allosteric pocket on the external receptor interface with the lipid bilayer (Figure 13). 
 
 
Figure 13: Compounds 7 and 13 co-crystallised into the hP2Y1R showing the two distinct 
binding sites. An overlay of structures pdb codes 4XNV and 4XNW visualised with PyMOL 
Molecular Graphics System, Version 1.3. Schrödinger, LLC. 
Perspective comment 
 The story of the discovery of 27, covered over several papers, illustrates a classical 
medicinal chemistry project where core pharmacological optimisation (P2Y1R antagonism) 
was run in multi-parameter optimisation to improve physico-chemical properties (such as 
solubility and pharmacokinetics) of the lead compounds. It is also important to note that 
during this optimisation phase, consideration of all parts of the structure was examined 
including the utilisation of bioisosteric replacements (Figure 14). 
 
Figure 14: Summary of the discovery of 27. cLogD is the calculated distribution coefficient. 
While this optimisation process led to a dramatic increase in biological activity and 
improvement in solubility, increases in the core physical properties, such as MWt and 
lipophilicity, would lead to future issues in the development of a pre-clinical candidate.42 
Hopefully, elucidation of the co-crystal structure of the P2Y1R antagonist ligands will enable 
structure-based drug design of future P2Y1R antagonists, facilitating discovery of 
compounds with physical properties for improved oral absorption.  
Drug-like antagonists of the P2Y2 receptor (P2Y2R) 
The P2Y2R is activated by endogenous agonists UTP (hP2Y2, EC50 = 140 nM) and ATP 
(hP2Y2, EC50 = 230 nM) with almost equipotent activity in a transfected 1321N1 human 
 astrocytoma cell line.43 The P2Y2R is predominately Gq-coupled and receptor agonism leads 
to activation of phospholipase C (PLC), IP3 release and elevation of intracellular Ca2+ 
concentration, as well as the activation of protein kinase C (PKC) and activation of the 
mitogen activated protein kinase (MAPK) cascade.44 
 
P2Y2R agonism has shown potential as a treatment for cystic fibrosis (CF), as defective 
chloride secretion in the respiratory epithelium of CF patients can be compensated by 
activation of chloride secretion channels. Through a knockout study,45 comparison of 
P2Y2R(+/+) with P2Y2R(-/-) mice revealed that the P2Y2R mediated 85-95% of nucleotide-
stimulated chloride secretion in the trachea, and agonist 39 (INS37217, hP2Y2, EC50 = 220 
nM) was shown to increase chloride and water secretion, as well as an increased mucin 
release of tracheal tissue in an ex vivo model.46 It has also been shown that receptor 
agonism of the P2Y2R leads to keratinocyte proliferation47 and neutrophil migration,48 
suggesting that receptor antagonists could show promise in treating psoriasis. Offermanns et 
al49 reported that ATP released from tumor cell-activated platelets and induced the opening 
of the endothelial barrier, leading to migration of tumor cells and hence cancer-proliferation. 
More importantly they identified P2Y2Rs as the primary mediator of this effect; demonstrating 
a strong reduction of tumor cell metastasis in P2Y2R deficient mice and showing the 
therapeutic potential of P2Y2R antagonists as anti-metastatic agents. 
The only reported development of P2Y2R antagonists from an industrial research group are 
compounds patented by scientists at AstraZeneca in the late 1990s (formerly Fison’s and 
Astra Pharmaceuticals). Unfortunately, no absolute potency values for the compounds were 
 reported and so a detailed SAR cannot be given here. However, looking chronologically at 
the patents, it is possible to see the sequential development of several structurally distinct 
classes of receptor antagonists, culminating in compounds which could be classed as drug-
like. 
 
Figure 15: P2Y2R antagonists patented by AstraZeneca. All exemplified compounds were 
reported as being P2Y2R antagonists with a pA2 > 4.0 in hP2Y2R transfected Jurkat cells. 
cLogP was calculated using instant J Chem.50   
Within the first patent, a series of triphosphate receptor antagonists were reported (Figure 
15).51 It was shown, in an analogous series of P2Y2R agonists, that taking UTP as the 
starting point and replacing the βγ-oxygen with a dichloromethylene group, along with 
conversion to a 4-thiouridine, induced enhanced metabolic stability as well as maintaining 
full agonist activity.52 Conversion to a P2Y2R antagonism profile was achieved through the 
introduction of a large, lipophilic group at the C-5 position of the uridine. This key substitution 
was extensively exemplified with a biphenyl and dibenzo-suberenyl substituent 40 and 41 
respectively; however further substituents are reported throughout the patent.51 The in vivo 
use of these triphosphate analogues would probably be limited to intravenous and topical 
administration. With the scope of developing oral, drug-like compounds, there is a desire to 
move away from excessively high molecular weight and highly-charged triphosphate 
 moieties. To this extent, a subsequent patent53 was published detailing acidic, non-
phosphate P2Y2R antagonists, exemplified by 42 and 43 (Figure 16). 
 
Figure 16: P2Y2R antagonist patented by AstraZeneca. All exemplified compounds were 
reported as being P2Y2R antagonists with a pA2 > 4.0 in hP2Y2R transfected Jurkat cells.   
Within this second series of acidic receptor antagonists, it is possible to see distinct 
structural changes. Across the majority of the exemplified compounds, the core 4-thiouridine 
was maintained along with the dibenzo-suberenyl substituent, now further substituted with 
two additional methyl groups. Presumably these features were required to maintain or 
enhance the activity seen in the first series of compounds.  
In this series, the ribose group was replaced with a simpler 5-membered heterocycle, in 
most cases a substituted furan ring. In addition to this modification, a further notable 
structural change was replacement of the triphosphate with an acidic phosphate mimetic. 
This modification was reported as L-aspartic acid derivative 42 and the acyltetrazole 
analogue 43 (AR-C118925XX), along with other bioisosteric replacements. However, in 
achieving this structural change, a substantial increase in the overall lipophilicity was 
observed that would compromise their physico-chemical properties.  
  
Figure 17: P2Y2R antagonists patented by AstraZeneca including acidic (such as 44) and 
neutral receptor antagonists (such as 45-46). 
A series of less lipophilic receptor antagonists were reported in the final patent and a 
selection of these compounds is shown (Figure 17).54 The key strategy appeared to be 
replacement of one of the phenyl rings in the dibenzo-suberenyl substituent with a 5-
membered heterocyclic ring. This can be shown through considering 44 (cLogP = 3.3) which 
is appreciably less lipophilic than 43 (cLogP = 5.3) whilst remaining structurally similarity. 
More importantly, this change allowed for generation of a neutral receptor antagonist series 
as exemplified by 45 and 46. Although there have been no further reports on the activity of 
these compounds, structurally they appear to be more drug-like than the compounds in the 
previous patent applications.  
Since disclosure of these P2Y2R antagonists from AstraZeneca, several studies using 43 
with success in both in vivo and ex vivo models have been reported; further validating the 
therapeutic benefit of P2Y2R antagonists. In 2004, scientists at Novartis55 showed that 43 
was inactive at 10 μM concentrations against a panel of 37 receptors (except for hP2Y2). In 
an ex vivo model 43 concentration-dependently antagonized ATPγS-induced mucin 
secretion in human bronchial epithelial cells (IC50 ~ 1 M).  In 2015, Ceruti et al56 showed 
that in an in vivo model, 43 completely inhibited satellite glial cell activation and cross talk 
 with trigeminal neurons, exerting a potent anti-allodynia effect. This suggests P2Y2R 
antagonists also have therapeutic potential for management of trigeminal neuralgia. 
It has been reported57 that several members of the flavonoid family displayed P2Y2R 
antagonism (mP2Y2R, IC50 ≈ 10-50 µM). When screening a series of 40 flavonoids (Figure 
18), 48 (Tangeretin, mP2Y2R, IC50 = 12 µM) reduced the amplitude of the P2Y2R response 
to UTP but not the EC50 value, indicating it could be acting as an allosteric P2Y2R antagonist.  
 
Figure 18: A series of 40 flavonoids 47 (generic structure) and 48 
More recently it has been suggested58 that amphiphilic phytochemicals, similar to these 
flavonoids, appear to function indirectly through disruption of cell membranes in which the 
transmembrane proteins reside. This might explain the non-competitive antagonism 
observed for 48 and the difficultly encountered in extracting meaningful SAR from the 
compound series. However more importantly, the promiscuity in developing polyphenolic 
compounds is well known and is generally avoided when selecting lead-like compounds. 
From the unselective, broad-spectrum P2YR antagonist 49 (Reactive Blue-2, hP2Y2R, IC50 
=1.85 μM), a series of receptor antagonists were reported (Figure 19).59 The most potent (50 
hP2Y2R, IC50 = 9.82 μM), although unpublished, ‘appeared to be selective versus other P2Y 
subtypes as well as nucleotide-metabolizing enzymes’. 
  
Figure 19: Evolution of 50 (PSB-716) and 51 (PSB-416) from 49  
To develop a greater understanding for the binding of these P2Y2R antagonists, work was 
reported60 on site-directed mutagenesis studies, to understand the binding modes of UTP, 49 
and 50 (hP2Y2R, IC50 = 11.5 μM). It is worth highlighting several of these point mutations as 
they provide insight into ligand binding within the P2Y2R. 
Table 4: Mutagenesis data for selected P2Y2R antagonists 
Mutant UTP 49 51 
 EC50/μM IC50/μM IC50/μM 
wt4 0.0590 1.85 21.7 
Y114A 0.0372 >>100 24.6 
R272A 20.60 nd nd 
C278S 2.09 1.05 3.44 
wt3 0.0804 1.62 21.9 
Y198A 0.108 9.30 21.1 
S296A >>300 nd nd 
With respect to the receptor expression, mutants Y114A, R272A and C278S can be 
compared to wt4; mutants Y198A and S296A can be compared to wt3. 
 
 Mutation Y114A on the TM3 domain and Y198A on the TM5 domain did not significantly 
affect the UTP response, but did affect the antagonistic response of 49 but not 51. Mutation 
S296A on the TM7 domain significantly affected the agonistic response to UTP and similarly 
mutation R272A on the extracellular loop 3 (EL3) in close proximity to the TM6 domain, 
resulted in a significant loss of agonist response to UTP. The mutation C278S significantly 
affected agonist response to UTP. It was proposed that this mutation inhibited formation of a 
key Cys25-Cys278 disulfide bridge, which is thought to be important for the increase in 
receptor antagonism observed for 49 and 51.  
From this mutagenesis data, a bovine rhodopsin-based P2Y2R homology model was 
developed. It was hypothesized that Arg272 has a ‘gatekeeper’ role, helping to ‘guide’ the 
phosphates of the agonists into the receptor. Ser296 is located at the bottom of the binding 
pocket where it forms key hydrogen bonding networks with the nucleobase of UTP and ATP. 
A docked antagonist-binding pose of 50 was reported. However, even with the publication of 
this homology model in 2009 no further development of these compounds has been 
reported.  
Recent crystal structures of P2Y12R10 show significant difference in antagonist and agonist 
bound conformations. In the absence of an X-ray crystal structure for the P2Y2R, further 
work into developing P2Y2R homology models, focusing on antagonist receptor binding 
could prove invaluable for future development of drug-like P2Y2R antagonists. 
 
Antagonists of the P2Y4 receptor (P2Y4R) 
The hP2Y4R is fully activated by the endogenous agonist UTP (hP2Y4, EC50 = 550 nM, 
rP2Y4, EC50 = 200 nM) in transfected 1321N1 cells and is considerably more potent than 
ADP and UDP. ADP was shown to be a weak, partial agonist (hP2Y4, 15% max at 100 μM, 
rP2Y4, 34% max at 100 μM) and the weak agonist activity, sometimes observed for UDP, 
can be attributed to contaminating UTP. Interestingly, there are disparate differences when 
comparing the pharmacological properties of ATP on human and rat P2Y4Rs. In human, 
 ATP acts as a competitive antagonist (hP2Y4, pA2 = 6.2) whereas in rat, ATP acts as a full 
agonist (rP2Y4, EC50 = 1.17 μM).61 Mutagenesis work has shown that residues on the second 
extracellular loop (EL2) of the P2Y4R were responsible for ATP’s ability to act as an agonist 
in rat and an antagonist in human. In the triple hP2Y4R mutant (S177N, V183I, R190L), ATP 
was an equipotent agonist compared to UTP.62  
The first selective P2Y4R agonist 52 (hP2Y4, EC50 = 23 nM) was reported in 2011 and 
showed a 28-fold and 32-fold selectivity versus the P2Y2R and P2Y6R respectively (hP2Y2, 
EC50 = 640 nM; hP2Y6, EC50 = 740 nM). Through development of CXCR4-derived P2Y4R 
homology models, the selectivity gain was thought to be due to unconserved residues in the 
EL2 domain.63  
 
In a similar manner to the P2Y2R, activation of the Gq-coupled dependent pathways of 
P2Y4R leads to stimulation of chloride secretion channels and water secretion. Work with 
P2Y4-deficient mice showed P2Y4R expression in liver, stomach and intestine.64 It was 
shown that the P2Y4R was the primary mediator of UTP-stimulated chloride secretion in both 
small and large intestines, suggesting the potential use for the development of P2Y4R 
antagonists as anti-diarrheal agents.65 
Unlike most P2Y receptors, the P2Y4R does not show the same susceptibility to broad-
spectrum P2YR antagonists and is only antagonized by 49. Using hP2Y4R stably transfected 
into 1321NI cells, 53 (suramin) gave no antagonistic response and 54 (pyridoxal phosphate-
6-azo(benzene-2,4-disulfonic acid) tetrasodium salt hydrate (PPADS)) was shown to be 
relatively ineffective.66 Compound 49 was demonstrated to be a competitive P2Y4R 
antagonist in rat transfected Xenopus oocytes (rP2Y4, pA2 = 6.43).67 It is thought that the 
 P2Y4R may play a causative role in hypoglycemic cell death and, using 49, it was shown that 
P2Y4R antagonism increased cell survival in both cerebellar granule neurons and HEK-293 
cells under hyperglycemic conditions.68 This gives scope for future P2Y4R antagonists to be 
used as neuroprotective agents in diabetes. As with P2Y2, there is scope to use 49 as a 
starting point for the development of selective anthraquinone-based P2Y4R antagonists.  
 
  
However, there has been no further published work on any P2Y4R antagonists. Hence, there 
remains a large scope and unmet need for the development of lead- and drug-like P2Y4R 
antagonists. 
Antagonists of the P2Y6 receptor (P2Y6R)   
The P2Y6R receptor is activated by UDP (EC50 = 0.30 μM). Its transcript has been detected 
in numerous organs, including spleen, thymus, intestine, blood leukocytes and the aorta. 
The majority of research has been performed on agonists of this receptor as typified by 55 
(PSB0474)69 and 56 (MRS2957). 
 
 From these studies, it was shown that activation of the P2Y6R amplifies mucosal ATP 
release underlying bladder over-activity in patients with benign prostatic hyperplasia. 
Therefore, a potential use of a selective P2Y6R antagonist could be as a novel strategy to 
control persistent storage symptoms in obstructed patients.70 In a recent article, Hirota et al 
suggested that a P2Y6R  antagonist could have benefit in Clostridium difficile toxin-induced 
CXCL8/IL-8 production and intestinal epithelial barrier dysfunction and may therefore provide 
a new therapeutic target for the treatment of C. difficile infections.71 In a further recent study, 
it was shown that endothelium-dependent relaxation of the aorta by UDP was abolished in 
P2Y6 KO mice with the authors postulating that these observations might be relevant to 
several physio-pathological conditions, such as atherosclerosis or hypertension.72 Inhibition 
of P2Y6R  has also been suggested as a potential therapeutic target for monosodium urate 
(MSU)-associated inflammatory diseases, such as tophaceous gout.73 With these and other5 
recent observations, inhibition of the P2Y6R could prove a viable therapeutic mechanism in 
many potential disease areas. Unfortunately, there are only a few known non drug-like 
inhibitors of the P2Y6R  (57-58) available.74,75,76 
Fischer et al. recently described the SAR of uracil nucleotide derivatives and found that 
uridyl phosphosulfate (59) was a weak P2Y6R antagonist (Figure 20).75 
 
Figure 20: Known P2Y6R antagonists; 57 (MRS2578), 58 (MRS2567) and 59  
Even though these compounds have been used to study the potential therapeutic role of 
P2Y6R antagonism, the combination of their chemical functionality and bulk physical 
properties make them less than optimal starting points for oral drug discovery programs.77 
 Antagonists of the P2Y11 receptor (P2Y11R) 
The P2Y11R was cloned from human placenta and genomic DNA libraries.78 It is coupled to 
both Gq and Gs with its activation leading to increases in cAMP and IP3 levels. The rank 
order of potency of a series of nucleotides for the P2Y11R, transfected into two cell lines, 
1321N1 astrocytoma cells and CHO-K1 cells, is: ATPS ~ 
BzATP>dATP>ATP>ADPS>2MeSATP.79 P2Y11 mRNA has been found to be highly 
expressed in macrophages, platelets, lymphocytes, neutrophils, megakaryocytic cells and 
has also been detected in neuronal-derived and glial-derived cell lines.80 
The P2Y11R is expressed on some leukocyte types including monocytes,81 neutrophils,82 
lymphocytes and monocyte-derived dendritic cells.83 It has been found to mediate ATP-
induced maturation and regulate trafficking of specific dendritic cell types,84–86  regulate 
macrophage activation87 and regulate release of cytokines such as IL-6,88,89 IL-8 and the 
production of IL-12.90 It has also been shown that inhibition of neutrophil apoptosis by ATP is 
mediated by the P2Y11R.91 
The SAR of a series of suramin-derived P2Y11R antagonists have been investigated.92 In this 
study, the methyl groups of (53) were replaced by a range of substituents (Table 5).  
Table 5: Structure activity relationship of suramin analogues 
 
R P2Y1* P2Y2* P2Y11 pKi **  
H 59.3 31.6 6.95 
 CH3 (53) 54.5 50.5 6.52 
C2H5 48.7 48.8 6.00 
CH(CH3)2 45.0 31.1 6.35 
Ph 75.1 73.2 6.52 
F (60, NF157) 63.3 42.8 7.35 
Cl 40.6 55.2 6.97 
OMe 23.2 44.9 7.12 
CH2OCH3 47.5 44.3 5.62 
*Percentage inhibition by a single dose (100 M) of agonist-induced calcium mobilization of 
native P2Y1R and P2Y2R in HEK293 cells and at P2Y11R recombinantly-expressed in 
1321N1 astrocytoma cells). **The pKi values for P2Y11R on 1321N1 astrocytoma cells are 
shown. 
Interestingly, the same changes to structurally simpler compounds (61a-h) gave compounds 
with little or no antagonism at P2Y11 (Figure 21). 
 
Figure 21: Synthetic changes to 61a-h gave compounds with little or no activity at P2Y11 
A wide range of substituents were tolerated with the difluoro-substituted analogue, with 
compound 60 being the most potent (P2Y11, pKi = 7.35). This analogue, as well as having 
significant selectivity over P2Y1R and P2Y2R (> 650-fold), has 3- to > 67-fold selectivity over 
P2X2,3,4,7. 
 A systematic screening of a library of naphthalene phosphonic acid and sulfonic acid 
compounds led to the identification of 62 (P2Y11, pKi = 7.8). This compound was 2.6-fold 
more potent than 60 and almost 1000-fold more potent than its very close structural 
analogue 61b. At concentrations up to 100 M there were no observed effects at the P2Y1R, 
P2Y2R and P2Y6R (expressed in 1321N1 astrocytoma cells). 
 
A rat formalin-induced inflammatory pain model, using the selective P2Y11R antagonist 62 
(NF340) and agonist 63 (NF546), suggested that activation of the receptor, along with 
activation of the P2Y1R and P2Y6R, lead to nociception.92-93 
A computational model using the -bovine rhodopsin crystallographic structure as a 
template in combination with site-directed mutagenesis was used to deduce the key ATP-
binding site interactions. ATP was 10-fold less potent at the E186A mutant P2Y11R and 
1000-fold less potent at the R268A mutant, whilst being functionally inactive at the R106A 
and R307A mutants. It is proposed that Arg106, Arg268, Arg307 and Glu186 are involved in ionic 
interactions with the tri-phosphate chain. Arg307 may also be H-bonded to the adenine N6. 
Computational modelling also suggests Ser206 is involved in an interaction with the -
phosphate of ATP and Met310 interacts with the adenine ring.94-95 
Drug-like antagonists of the P2Y12 receptor (P2Y12R) 
The P2Y12R is found on many cell types including megakaryocytes and platelets. The 
endogenous agonist is ADP and, following a thrombotic event, activation of the P2Y12R 
amplifies platelet activation and aggregation, leading to thrombus formation.96 Although the 
involvement of ADP in platelet aggregation was first discovered in the 1960s,96-97 it was not 
 until 2001 that the P2Y12R was structurally characterized.98-99 Activation of both P2Y1R and 
P2Y12R are important for platelet activation and thrombus formation. However, the wide 
distribution of the P2Y1R amongst different cell types compared with the P2Y12R have made 
P2Y1R antagonists a less desirable target in drug discovery for treatment and prevention of 
thrombosis. 
The thienopyridine class of irreversible binders for the P2Y12R was discovered in the 1970s 
by researchers at Sanofi, whilst screening compounds with structural similarity to the 
nonsteroidal anti-inflammatory drug tinoridine; although it is interesting to note that the actual 
drug target was not known at this time.100-101 It was shown that some of these compounds 
did not exhibit anti-inflammatory properties but did have an anti-thrombotic effect after oral 
dosing in a rat model. One of the most effective compounds 64 (ticlodipine) was chosen for 
development and was launched in 1978 as an anti-thrombotic agent for a range of high risk 
patients. Unfortunately, (64) was found to suffer from a poor benefit/risk ratio and a backup 
program resulted in the launch of 65 (clopidogrel) in 1998, which had a much improved 
safety profile. Interestingly, 65 was initially tested as a racemate, but it was eventually found 
that the anti-thrombotic activity resided with the S-enantiomer.101 
This class of inhibitor required activation through conversion to the active metabolite 66, 
which binds irreversibly to the receptor. Binding to the P2Y12R was confirmed in 2001102  and 
site-directed mutagenesis identified two extracellular cysteine residues, Cys17 and Cys270 as 
candidates for disulfide bond formation with this active metabolite103 which was later 
confirmed when the X-ray crystal structure was published in 2014.13 
In 2009, another irreversible inhibitor within this class 67 (prasugrel - a racemate) was 
launched.104 
  
AstraZeneca scientists took the weak P2Y12R antagonist ATP as the starting point for their 
discovery project. Replacement of the -oxygen with a dihalomethylene group and 
installation of substituents on the adenine ring gave a series of high affinity reversible 
antagonists.105 One of these, 68 (cangrelor, P2Y12 IC50 = 0.4 nM), was approved in 2015 for 
use as a quick onset/quickly reversed intravenous antiplatelet drug, over twenty years from 
its discovery. 
 
The next objective was to develop a drug suitable for oral administration. This required a 
move away from compounds containing highly acidic groups.101 As ADP is an agonist for the 
P2Y12R and ATP an antagonist, it was hypothesized that the terminal phosphate was 
important for receptor antagonism. Effort was therefore directed at finding alternative acidic 
groups to the triphosphate chain, in particular the terminal phosphate.  This work led to the 
aspartic acid-derived analogues 69-71. Within this series, conversion of the purine ring to a 
triazolopyrimidine 70 gave a > 100-fold increase in binding affinity over the purine analogue.  
Replacement of the ribose with a cyclopentyl ring gave a series of compounds, such as 71, 
with similar activity and increased metabolic stability (Figure 22).   
  
Figure 22: Key SAR of glycoside analogues showing the evolution to the potent cyclopentyl 
analogue 71. Affinity pIC50 values were derived from an ADP-induced aggregation assay 
using washed platelets. 
The physical properties of these molecules (MW>500, >5 H-bond donor groups and the 
dicarboxylic acid moiety) were not conducive to good oral absorption. Replacement of the 
butylamine group on the triazolopyrimidine ring with a 1R,2S-trans-phenylcyclopropylamine 
gave an increase in potency across a number of analogs. Further modifications aimed at 
finding a suitable replacement for the dicarboxylic acid led, with fluorine fine tuning, to 72 
(ticagrelor),106 an orally active reversible P2Y12R antagonist, which was launched in Europe 
in 2010 (hP2Y12 pKi 8.7; rat PK CL 21 mL/min/kg; Vss 3.8 L/kg; T1/2 2.6 h, F 24%).   
 
Outside of the work patented by AstraZeneca other companies have developed other 
nucleotide-based P2Y12R antagonists. Inspire Pharmaceuticals reported the 
monophosphate, 73 (INS50589, IC50 16 nM) that showed inhibition of platelet aggregation in 
a washed human platelet assay. Unfortunately, this compound proved unsuccessful in 
clinical trials as an intravenously-delivered drug.107 Further carboxylic acid replacements for 
 the phosphate groups were investigated with the 2-carboxybenzyl analogue 74 (hP2Y12, IC50 
= 40 nM) being the most potent of this series. 
 
A series of analogues of 72, primarily focussed on replacing the hydroxyethoxy substituent 
with a heterocycle, was reported by researchers at Johnson & Johnson. Compounds 
containing the 1H-tetrazol-5-yl group were the most potent (e.g.  75, hP2Y12, Ki = 2 nM). No 
in vivo data was reported.108 
A number of ester and carbonic ester derivatives (76a-d) of 72 and 77 (a major metabolite of 
72 with similar binding affinity) have a comparable effect to 72 and 77 on platelet 
aggregation after oral dosing (5 mg/kg) to rats. No in vitro data was given and the activity is 
assumed to be due to hydrolysis (presumably metabolic) to 72 and 77 (Figure 23).109 
 
Figure 23: Derivatives of 72, 76a-d and 77 - the active metabolite of 72. 
 More recently,110 researchers at Shanghai Hengrui Pharmaceutical Co Ltd. described their 
SAR exploration of the cyclopentyl ring and cyclopropylamino groups of 72. Compound 78, a 
fluorinated analogue of 77, was more potent than 72 in vitro and in vivo, with a satisfactory 
PK profile and a shorter bleeding time observed. 
With the scope of developing non-nucleotide antagonists, high throughput screening of the 
AstraZeneca compound bank identified piperazinyl-pyridine, 79 as a hit (hP2Y12 IC50 = 330 
nM). SAR investigations were amenable to parallel synthesis and this eventually led to acyl 
sulfonamide 80 (AZD1283, hP2Y12 IC50 = 11 nM), a compound with a PK profile suitable for 
progression into human clinical trials.111–113  It is interesting to note that an acyl 
sulphonamide group is also present in 81 (elinogrel), a P2Y12R antagonist which progressed 
into clinical trials supported by Portola Pharmaceuticals,114 then by Novartis. However, 
development of this compound was terminated in 2012. 
 
With the use of fusion protein, the crystal bound structures of the P2Y12R with full agonist 2-
methylthio-adenosine-5’-diphosphate (2-MeSADP), 2-methylthio-adenosine-5’-triphosphate 
 (2-MeSATP) and 80 have been published.13-14 Both 2-MeSADP and 80 bind in the same 
pocket with the adenine group of 2-MeSADP and the nicotinate group of 80 forming similar 
 interactions with Tyr105. However, the pocket shape in these structures is different and 2-
MeSADP and 80 display only a partial overlap. It is interesting to note the movement in TM7 
observed for binding of 80 in the antagonist-bound P2Y12R state compared to that of the 
agonist-bound P2Y12R state (Figure 24). 
 
 
Figure 24: a) Overlay of agonist (cyan) and antagonist (brown) bound P2Y12Rs with 80 and 
2MeSADP. b) Crystal structure of 80 in an antagonist-bound state P2Y12R c) Methylthio-
adenosine-5’-diphosphate (2-MeSADP) in the agonist-bound state P2Y12R. An overlay of 
structures pdb codes 4PXZ (brown) and 4NTJ (cyan) visualised with PyMOL Molecular 
Graphics System, Version 1.3. Schrödinger, LLC. 
 The 2-thioether group occupies a lipophilic pocket formed by Phe106, Lys155, Ser156 and 
Asn159, providing an explanation for the affinity enhancing effect of the alkylthio group. The 
2-MeSATP structure has a similar conformation to 2-MeSADP. Furthermore, 82, 83 and 68, 
with the modified triphosphate chain and larger 2-alkylthio substituent, can be docked in a 
similar way to 2-MeSADP within the binding cavity of P2Y12R-2-MeSADP, suggesting the 
reason for receptor agonism and antagonism is unclear. The docking of 72, with the large N6 
substituent, requires conformational change of the receptor in order to be accommodated. 
 
Berlex Biosciences reported 115 that the piperazinyl-glutamate 84 (BX-667, hP2Y12 IC50 129.9 
nM) and its active metabolite 85 (BX-048, IC50 8.3 nM), are reversible antagonists for the 
P2Y12R in an in vitro ADP-induced washed platelet aggregation assay.116 The compounds 
were shown to inhibit platelet aggregation and thrombus formation in vivo in both rat and dog 
models.117  
 
Taking 84 as a starting point, scientists at Pfizer used parallel synthesis to find a 
replacement for the quinoline ring (Figure 25).118,119,120 
  
Figure 25: Chemical expansion of 84 illustrating the range of compounds prepared 
A large number of substituted heterocycles were evaluated (group R3 in Figure 25) and it 
was found that a nitrogen atom in the ring ortho- to the amide was preferred along with a 
phenyl ring ortho- to the same nitrogen (Figure 26). 
 
Figure 26: A series of substituted heterocyclic P2Y12R antagonists 
Optimization showed that R4 could be a wide variety of substituents and did not need to 
contain an acidic group. Compound 86 (hP2Y12, Ki = 15 nM), which contains only one 
carboxylic acid group, was found to have the best overall profile, with a PK and safety profile 
suitable for pre-clinical evaluation. Further refinement121 gave the closely related compounds 
87-88, with activity (87 hP2Y12 Ki 2.1 nM, 88 hKi 2.8 nM) and PK profiles suitable for clinical 
backups. 
  
 Actelion122 reported the development of P2Y12R antagonists using 85 as the starting point, 
leading to 89, which is structurally similar to 86-88. This compound has very good activity 
(hP2Y12R IC50 = 4.8 nM) and a PK profile suitable for further evaluation.  In a later paper123 
replacement of the carboxylic acid was investigated. A number of acidic carboxylic acid 
bioisosteres, including acyl sulphonamides, tetrazole and 3-hydroxyisoxazole exhibited 
similar potencies to the parent compound, with the phosphonic acid derivative, 90 
(ACT246475) chosen as the pre-clinical candidate. Unfortunately, the bioavailability was 
found to be low in both rat and dog. This led to the development of the 
bis((isopropoxycarbonyl)oxy)methyl ester pro-drug 91 (ACT281959). 
 
Sanofi-Aventis124 found the 1-phenylpyrazolone scaffold 92 (hP2Y12 Ki = 139 nM) as a 
suitable replacement for the quinoline ring of 84. A comparison of 92 and 84 docked into a 
 P2Y12 homology model showed the 1-phenylpyrazolone moiety of 92 occupies the same 
hydrophobic pocket as the quinoline group of 84. The 5-substituent of the 1-
phenylpyrazolone, which did not overlay with the 4-substituent of quinoline of 84, was 
selected for systematic change; followed by variations to the piperazine ethyl carbamate and 
the central amino acid group. Optimization led to the neutral antagonist 93 (hP2Y12 Ki = 7.7 
nM). Removal of the acidic moiety led to a substantial reduction of PPB to give high activity 
in the human platelet rich plasma assay (hPRP IC50 = 30 nM). Compound 93 showed anti-
aggregator activity in an ex-vivo dog model (10 mg/kg, p.o.), showing the potential for pre-
clinical development.  
 
Pfizer reported thienopyrimidine-based P2Y12R antagonists125 with the most potent examples 
being 94 (hP2Y12 Ki = 4 nM) and 95 (hP2Y12 Ki = 3 nM). However, a significant drop in 
activity was observed in the hPRP assay (3 and 5 M respectively), which was attributed to 
the highly hydrophobic biphenyl group.  
  
Taking the HTS hit 96 (P2Y12 IC50 = 1.5 M) as a starting point, Sanofi-Aventis developed 97 
(SAR216471) as a pre-clinical candidate.126 With high binding affinity (IC50 = 17 nM), the 
compound exhibited a small activity drop-off in the hPRP assay (IC50 = 100 nM) resulting in 
good activity in the ex-vivo rat platelet aggregation model (ED50 = 2.75 mg/kg p.o.). A 
number of anthraquinone derivatives have been found to be selective, high affinity P2Y12R 
antagonists, the most potent of which are 98 (hP2Y12 Ki = 25 nM) and 99 (hP2Y12 Ki = 21 
nM).127,128  Compound 100 (hP2Y12 IC50 = 170 nM) was found after screening the COR 
compound library.129 Limited investigation of the SAR through simultaneous changing of the 
ethoxy groups failed to find more potent analogues (Figure 27).  
 Figure 27: A selection of P2Y12R antagonists from Sanofi-Aventis and 100 (CT50547) 
discovered through screening the COR screening collection.  
Perspective comment 
The important role the P2Y12R plays in thrombus formation and the huge commercial 
success of clopidrogrel, has meant that a number of pharma companies have invested 
significantly in P2Y12R antagonist programmes.  
The thienopyridine class of irreversible binders was discovered incidentally in rat and mouse 
in vivo and ex-vivo anti-inflammatory screens. The requirement for metabolic transformation 
to an active species for P2Y12R activity means that compounds, within this series, would be 
inactive in either a cellular or membrane-based HTS assay. Furthermore, the active 
metabolite 66 is chemically unstable and would not therefore be present in a compound 
screening library.  
 The risks involved in developing an irreversible antagonist and its potential for deleterious 
binding to proteins could be seen as being prohibitive to most pharmaceutical groups. As a 
consequence, P2Y12R antagonist programmes have focussed on finding reversible receptor 
antagonists. The first of these company programs, Fison’s Pharmaceuticals, before the 
advent of high throughput screening, used ATP as a starting point. It is commendable that 
these investigators were able to develop an oral drug, ticagrelor, from such a non-lead-like 
chemical starting point. 
Antagonists of the P2Y13 receptor (P2Y13R) 
The P2Y13R was first identified at the turn of this century,130,131 with its primary sequence 
demonstrating a 48% amino acid homology with the P2Y12R.  Coupled to Gi, it is activated 
by a range of diphosphate adenine nucleotides (ADP, 2MeSADP, ADPβS).  A more 
thorough evaluation of the receptor revealed a number of key similarities and differences 
between the P2Y13 form of the receptor and its closely related P2Y12 subtype.132 P2Y13 is 
less sensitive to activation via triphosphate nucleotides, 2MeSADP displays a superior or 
equal potency to that of ADP depending upon the endpoint measurement and the receptor is 
only weakly antagonized by 83.105 In addition, the P2Y13R is not antagonized by the active 
metabolite of 66 at concentrations up to 2 μM.132 Meanwhile, the similarities between the two 
receptor subtypes were also revealing; both subtypes, for example, are antagonized by 
2MeSAMP, diadenosine tetraphosphate (Ap4A) and most interestingly 68 , with the latter 
behaving in a non-competitive manner with respect to the P2Y13R.  It was further noted that 
ADP activation of the P2Y13R could be antagonized by 49 (IC50 = 1.9 M), 53 (IC50 = 2.3 M) 
and 54 (IC50 = 11.6 M).  The P2Y13R is expressed in the brain, spleen lymph nodes and 
bone marrow where it is also expressed on hemopoietic cells.133 
To date, there remains a paucity of P2Y13 selective antagonists, with the main structural 
contribution arising from derivatives of 54.134 Recognizing that the pyridine derivative 54 had 
been previously identified as a low potency antagonist of the P2Y13R,132 Kim et al embarked 
 upon the design and synthesis of a range of new derivatives, assessing their pharmacology 
through attenuation of ADP-induced PLC activity in human astrocytoma 1321NI-Gα16 cells 
stably transfected with human P2Y13Rs (hP2Y13-1321N1- Gα16).  
 
The most potent compounds generated from this synthesis campaign were 101 (MRS2211 
hP2Y13 pIC50 = 5.97) and 102 (MRS2603 hP2Y13 pIC50 = 6.18).  102 demonstrated a 
competitive antagonism (hP2Y13 pA2 = 6.3) alongside a >20-fold selectivity towards the 
P2Y13R when compared to P2Y1 and P2Y12.  Its subsequent commercial availability has 
made it the molecular probe of choice for further investigation of P2Y13R subtype 
pharmacology.135–144 
Drug-like antagonists of the P2Y14 receptor (P2Y14R) 
The P2Y14R was, at its time of identification, the eighth member of the P2Y receptor 
family.145  It is a Gi-coupled receptor, which is activated by at least four naturally occurring 
UDP-sugars.  These include UDP-galactose, UDP-glucuronic acid, UDP-N-
acetylglucosamine and UDP-glucose (UDP-Glc), with the latter acting as the most potent 
agonist. P2Y14 mRNA has been detected in a range of human tissues including the stomach, 
intestine, adipose, brain, lung, spleen, heart and placenta.133 Additionally, this receptor has 
been found in neutrophils.146 Since UDP-Glc promoted signalling in multiple types of immune 
cells has been described; the P2Y14R may possess a role in regulation of immune system 
homeostasis.147 More recently, experiments with P2Y14 knockout mice have highlighted the 
potential of P2Y14R antagonism in the treatment of diabetes.148 
 Using a yeast model system, it was demonstrated that UDP antagonized the UDP-Glc 
promoted P2Y14R activation in a concentration-dependent manner.149 Cognisant of this 
report, Harden et al undertook a more detailed study to ascertain that UDP acted as a 
competitive antagonist at the human P2Y14R (pKB = 7.8).150  A similar level of receptor 
antagonism was observed using uridine 5’-O-thiodiphosphate whereas ADP, CDP and GDP 
produced no antagonist activity.  An interesting observation from this study identified a 
striking ortholog variance, whereby UDP was demonstrated to act as a potent agonist 
(rP2Y14R EC50 = 0.35 μM) highlighting a polarized pharmacological difference in ligand 
behaviour. The authors then reassessed the action of UDP in three different cell lines; 
human embryonic kidney (HEK) 293, C6 glioma, and Chinese hamster ovary (CHO) cells, all 
stably expressing the human form of the P2Y14R.151 This series of experiments ultimately 
concluded that UDP was in fact acting as an agonist with EC50 values of 74, 29 and 33 nM 
respectively in the previously highlighted cell lines. 
The first non-nucleotide based antagonists for the P2Y14R were originally reported by Merck 
and comprised a series of compounds based around a tetrahydropyrido[4,3-d]pyrimidine 
scaffold.152 The initial hit 103 was identified via an high-throughput calcium2+ mobilization 
assay screen of the Merck sample collection.  Whilst displaying only modest potency 
(mP2Y14 IC50 = 4.9 M), the scaffold was seen as attractive to pursue a hit-to-lead 
optimization programme; comparing activity at both the mouse and chimpanzee orthologs of 
the P2Y14R. The authors comment that the selection of chimpanzee P2Y14 (99% sequence 
homology to human) for screening was driven by the larger window (signal/background 
noise) with this receptor over the human P2Y14, while the mouse receptor (83% identical to 
human) was used to enable future evaluation of the compounds in mouse models of 
disease.  Systematic modification of the substitution pattern on the phenyl urea moiety 
eventually revealed that a 3,4- or 3,5-disubstitution pattern afforded the most potent 
antagonists as long as the 3-position substituent was an ethyl group, e.g. 104 (Figure 28).   
  
Figure 28: The first non-nucleotide based antagonists for the P2Y14R. 
Turning their attention to the o-tolyl group at the 4-position of the heterocylic core generated 
a series of analogs highlighting that either ortho-positions could be substituted by either a 
methyl or chloro group, maintaining very good activity at both receptors, e.g. 105.  The final 
series of analogs retained the 3-ethylphenyl urea and the o-tolyl moieties and then altered 
the 3-pyridyl group to produce nineteen new compounds of which five are highlighted (Table 
6). 
Table 6: Antagonist potency of 2-aryl substituted tetrahydropyrido[4,3-d]pyrimidines on the 
mouse and chimpanzee P2Y14Rs.152 
 
Compound Ar Mouse P2Y14 IC50 
(μM) 
Chimpanzee P2Y14 IC50 (μM) 
106 3,4-(OCH2O)-Ph 0.010 0.081 
107 4-(CN)-3-Pyr 0.003 0.004 
108 5-pyrimidyl 0.012 0.008 
109 2-(CN)-5-pyrimidyl 0.001 0.001 
110 Me2-4-isoxazolyl 0.004 0.002 
 
 Compounds 107 and 109 were not progressed due to potent hERG potassium ion channel 
binding (<200 nM), whereas compounds 106, 108 and 110 displayed reduced hERG binding 
(>5 μM).  Preliminary in vivo analysis of these compounds when dosed as suspensions (50 
mg/kg p.o. or iv at 5 mg/kg i.v.) in C57B6 mice revealed compounds with high volumes of 
distribution and extended half-lives.  Compound 106 gave the best overall PK parameters 
and was considered suitable for further in vivo experiments to interrogate the 
pharmacological role of P2Y14.  Further characterization of 106 revealed that its antagonistic 
activity was mediated through a non-competitive manner with respect to UDP-mediated 
receptor activation. 
The Merck group followed this report with a back-to-back manuscript highlighting a different 
scaffold, a 4,7-disubstituted naphthoic acid 111, which had been identified as displaying 
antagonism of UDP-Glc activation (IC50 = 3.5 μM) of both the mouse and chimpanzee 
P2Y14R variants using the same assay methodology.153-154  Unlike 106, this compound 
exhibited competitive antagonism of 3H-UDP in a recombinant simian P2Y14 binding assay 
(Ki 0.16 μM).  A comprehensive SAR study focused upon substituents in the 3-, 4- and 7-
positions of the naphthoic acid scaffold and revealed 112 as the most potent compound 
whilst confirming the essential role of aryl substituents at the 4- and 7-positions.  
 
Early PK assessment of 112 was undertaken through oral dosing of C57BL/6 mice at 50 
mg/kg and i.v. administration at 2 mg/kg.  (F = 12%, T1/2 = 2.7 h).  Further studies identified 
that 112 was extensively metabolized via phase II metabolism (>99%) to the glucuronide 
and excreted via the bile. 
A second round of synthetic variants were synthesized in an attempt to attenuate this level of 
 glucuronidation through decreasing the electron density of the carboxylic acid moiety.  This 
ultimately led to identification of 113 as the best molecule in terms of its potency and PK 
profile (Ki = 4 nM, F = 67% (mouse) CL = 1.6 ml/min/kg, T½ = 3.0 h, Cmax = 113 μM). 
 
However, it was identified that 113 displayed high affinity for plasma proteins, being >99% 
bound in the presence of 4.5% human serum albumin (HSA).155  Further synthetic efforts 
identified zwitterion 114 as a compound which retained its pharmacological potency (Ki = 1.9 
nM in the chimpanzee P2Y14 binding assay) as well as displaying acceptable levels of HSA 
binding.  The latter assay was determined by using a binding assay incorporating 2% HSA 
for antagonist measurements.  Harden et al subsequently reported a more thorough 
evaluation of the pharmacology of 114.156 They successfully demonstrated that in C6 glioma 
cells stably expressing the P2Y14R, the concentration-effect curve of UDP-Glc for promoting 
inhibition of adenylyl cyclase was right-shifted in a concentration-dependent manner by 114.  
In addition, at a concentration of 1 μM 114 exhibited no agonist or antagonist effect at the 
P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12 or P2Y13Rs. 
The zwitterionic nature of 114 imbued detrimental effects upon its oral bioavailability (F = 
5%, C24h = 0.68 μM).  Therefore a series of ester derivatives were synthesized to investigate 
whether a pro-drug strategy would be beneficial. Of the ten esters described, four displayed 
good lability to afford high conversion rates to the parent drug 114 in the presence of whole 
blood. However of these, only 115 and 116 were able to replicate this in an in vivo setting 
with 116 being identified as the most promising candidate. 
  
Compound 116, when orally dosed in mice at 50 mg/kg, delivered plasma levels of 114 
(Fvirtual = 67%, C24h = 2.28 μM, AUC = 54 μM h and CL = 1.6 mL/min/kg) which were 
significantly higher than when 114 was administered as the free zwitterion (F = 5%, C24h = 
0.68 μM, AUC = 23 μM h). 
As a pharmacological tool, 114 was also identified as a potential congener for the 
development of a fluorescent tool for receptor interrogation.157  Molecular modelling studies 
of 114 bound to a homology model of the P2Y14R were undertaken, the model being 
constructed on the basis of X-ray crystal structures of the P2Y12R.13-14 Modelling established 
that the piperidyl nitrogen was suggested to be pointing towards the extracellular opening of 
the ligand binding pocket such that the charged piperidine nitrogen is solvent exposed and 
therefore a potential tether point on which to build a linker moiety. To this end an alkyl 
acetylene linker was appended to the piperidyl nitrogen to afford a congener primed for 
conjugation with an azide modified fluorophore via a copper-catalyzed [2+3] cycloaddition, 
ultimately affording Alexafluor488 117 and a BODIPY 630/650-X 118 fluorescent conjugates. 
  
117 exhibited exceptionally high affinity towards the P2Y14R (Ki = 80 pM) whereas 118 
displayed a much weaker interaction (Ki >100 nM) illustrating the critical influence of both the 
linker and the fluorophore on the final pharmacology of the conjugate.158 Fluorescent 
conjugate 117 was employed in flow cytometry studies to quantify specific binding to the 
P2Y14R and further utilized to confirm the binding selectivity’s and affinities of established 
P2Y receptor ligands. 
Conclusion 
Within the past 2 decades, numerous P2Y receptor antagonists have been reported in both 
peer-reviewed and patent literature. The therapeutic relevance and efficacy of some of these 
antagonists has been proven in vitro, ex vivo and in vivo. The most clinically relevant and 
successful antagonists to-date have centered on new anti-thrombotics targeting the P2Y12R. 
The serendipitous discovery of the thienopyridine class of irreversible P2Y12R binders led to 
the development and commercial success of clopidogrel (launched in 1998),101 followed by 
prasugrel (2009).104 Their successes encouraged numerous pharma-companies to invest 
into P2Y12R antagonist programs. It is commendable that taking ATP as a starting point, 
scientists at AstraZeneca developed the oral drug ticagrelor (2011);106 a program which has 
also led to the approval of cangrelor (2015).105 P2Y1R antagonists have also showed 
promise as anti-thrombotics and substantial research into developing suitable clinical 
candidates has been reported by scientists at BMS, Pfizer and GSK. To-date, it remains that 
no compounds have progressed to FDA approval.  Notwithstanding this fact, drug-like 
 compounds (e.g. 27 and 31) are available to further optimize, however the core physico 
chemical properties of these P2Y1R antagonists have no doubt hindered their clinical 
development. Outside of anti-thrombotics, antagonists of the other P2Y receptors show 
promise for the treatment of a variety of diseases. P2Y14R antagonists show potential as 
preventative agents for type-2 diabetes, with Merck reporting both potent competitive and 
non-competitive antagonists, with the pro-drug 116 being the most advanced and promising 
clinical candidate.155 Antagonists of the P2Y2R look to be therapeutically viable in a variety of 
conditions, with a growing body of evidence to support their use as anti-metastatic agents.49 
Several patents published by AstraZeneca reported the most relevant P2Y2R antagonists; 
with 43 being used by many research groups in in vivo and ex vivo studies.55,56 There is a 
need to develop drug-like P2Y2R antagonists which would further validate the therapeutic 
potential of P2Y2R antagonism in many disease states.  
In our opinion there are at present no drug-like P2Y4R, P2Y6R, P2Y11R and P2Y13R 
antagonists in the published or patent literature. The structural class of the majority of these 
antagonists can, with exceptions, be derived from the broad-spectrum P2 receptor 
antagonists:  49, 53 and 54. Although some of these have shown potency and selectivity, 
their overall physico chemical properties are not commensurate with good oral absorption 
and metabolic stability. With growing evidence for these receptors having a fundamental role 
in a variety of disease states, the identification of new lead-like compounds, will hopefully 
afford new P2YR clinical candidates.   
Throughout the identification and optimization of P2Y1, P2Y12 and P2Y14R antagonists, radio-
ligand binding and Ca2+ mobilization (FLIPR-based) HTS assays have been reported, that 
helped identify new lead-like receptor antagonists. Importantly, several fluorescent ligands 
have recently been reported for the P2Y2, P2Y4, P2Y6 and P2Y14 receptors.157,159,160 We feel 
that these, and future fluorescent ligands, could underpin fragment-based approaches to 
identify new lead-like antagonists of the P2Y receptors. These fluorescent ligands will also 
be of huge importance in interrogating the pharmacology of these receptors in healthy and 
diseased cell lines. The most significant recent development towards understanding the 
 binding of agonists and antagonists to P2YRs, has been the publication of ligand-bound 
P2Y1R12 and P2Y12R13,14 X-ray crystal structures. The homology models that have been 
reported for P2Y receptors have predominately focused on agonist-nucleotide binding. With 
this new structural information, and in-lieu of structural information for all P2Y receptors, 
there is now scope to develop antagonist-focused homology models across the two subsets 
of P2Y1-like and P2Y12-like receptors. This is something which will undoubtedly aid 
identification and optimization of new lead-like antagonists of P2Y receptors. 
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